Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) shares declined 1.55 percent to close at $18.40 a share Monday. The stock traded between $17.49 and $18.76 on volume of 7.59 million shares traded. Analysts at Oppenheimer have recently upgraded the company’s rating to "outperform" from "perform". Shares of Ariad Pharmaceuticals have fallen approximately 4.0 percent year-to-date.
Find out more about Ariad Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/ARIA
Curis, Inc. (NASDAQ: CRIS) shares declined increased 3.72 percent to close at $4.46 a share Monday. The stock traded between $4.23 and $4.49 on volume of 858,176 shares traded. Analysts at Chardan Capital Markets have recently initiated coverage on the company with a "buy" rating and a price target of $6.00. Shares of Curis have gained approximately 30.0 percent year-to-date.
Find out more about Curis including full access to the free equity report at:
www.RDInvesting.com/CUR
Endocyte, Inc. (NASDAQ: ECYT) shares declined 4.24 percent to close at $13.33 a share Monday. The stock traded between $13.28 and $14.11 on volume of 586,240 shares traded. Analysts at Chardan Capital Markets have recently initiated coverage on the company with a "buy" rating and a price target of $20.00. Shares of Endocyte have gained approximately 48.0 percent year-to-date.
Find out more about Endocyte including full access to the free equity report at:
www.RDInvesting.com/ECYT
ImmunoGen, Inc. (NASDAQ: IMGN) shares increased 2.04 percent to close at $17.02 a share Monday. The stock traded between $16.60 and $17.66 on volume of 986, 177 shares traded. Analysts at Chardan Capital Markets have recently initiated coverage on the company with a "buy" rating and a price target of $21.00. Shares of ImmunoGen have gained approximately 33.0 percent year-to-date.
Find out more about ImmunoGen including full access to the free equity report at:
www.RDInvesting.com/IMGN
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]